Progress in application of patient-derived organoid xenograft model in cancer precision therapy
10.3969/j.issn.1005-4847.2025.01.010
- VernacularTitle:PDO异种移植模型在肿瘤精准化治疗研究中的应用进展
- Author:
Yanzi XING
1
;
Jumei ZHAO
;
Changhong SHI
Author Information
1. 延安大学基础医学院,陕西延安 716000;空军军医大学实验动物中心,西安 710032
- Publication Type:Journal Article
- Keywords:
patient-derived tumor organoids;
xenograft;
precision medicine;
tumor heterogeneity;
drug susceptibility
- From:
Acta Laboratorium Animalis Scientia Sinica
2025;33(1):99-107
- CountryChina
- Language:Chinese
-
Abstract:
Precision therapy has become an important approach in modern medicine,with the goal of providing individualized treatment according to the characteristics of individual patients.The successful development of precision medicine depends on the application of preclinical cancer models.Patient-derived organoid(PDO)xenograft models display characteristics of both PDO models and in vivo patient-derived tumor xenograft models.This type of model can not only maintain the heterogeneity of the original tumor,but also has additional advantages,such as large-scale cultivation,high-throughput drug screening in vitro and drug sensitivity testing in vivo.It is an innovative,precise preclinical disease model.In this review,we summarize the basic characteristics of the PDO xenograft model,analyze its construction method and influencing factors,further discuss its application in precision therapy,with the aim of providing a reliable preclinical experimental tool for individualized cancer treatment.
